|
News Release 16th January 2007 DanioLabs and Senexis Announce Collaboration on Ageing Related Diseases DanioLabs, the neurology and ophthalmology drug reprofiling company, today announced the signing of a strategic collaboration with Senexis, a private drug development company, focused on discovering new treatments for ageing-related diseases. DanioLabs has pioneered development of medium/high throughput, high content in vivo assays utilizing its cutting edge zebrafish technology. Known drugs and pharmacological probes are screened with a view to minimizing the risk of drug development. It has two programmes with positive clinical data and a strong preclinical pipeline. DanioLabs has a major neurodegeneration programme covering Parkinson’s, Alzheimer’s and Huntington’s diseases, as well as multiple sclerosis. It is currently screening for small molecules which rescue the underlying pathologies of these disease states as well as ameliorating the cognitive impairment associated with various forms of dementias. Senexis is developing new chemical entities as inhibitors of amyloid-related toxicity and inflammation in Alzheimer’s disease. It is expected that the combination of the two complementary approaches will offer a significant opportunity to develop novel molecules with potential of becoming disease-modifying therapies for Alzheimer’s disease. Paul Goldsmith, CSO of DanioLabs said: “We are excited about this collaboration because it brings Senexis’ chemistry together with our biology. It marks an important transition for us as we move from assay development and validation to the process of identifying and progressing therapeutic candidate drugs”. "We are delighted to be collaborating with DanioLabs," commented Dr Mark Treherne, Senexis’ Chief Executive. “We look forward to a productive and fruitful collaboration”. For further information
please contact: Senexis Northbank Communications
Note to Editors: About DanioLabs DanioLabs is a biotechnology company focused on developing products in the fields of neurology and ophthalmology. The Company has a reprofiling strategy; identifying and enhancing known drug compounds for new, innovative therapeutic applications, with the aim of out-licensing products for further development and commercialisation. DanioLabs has a portfolio of clinical and preclinical programmes, with its drug discovery programmes supported by collaborations with the CIMR (Cambridge Institute for Medical Research) and Cambridge Centre for Brain Repair, at the University of Cambridge. Its Alzheimer models display amyloid-related pathology. Note to Editors: About Senexis Senexis is a drug development company,
dedicated to the discovery of effective treatments and diagnostics
for major ageing-related diseases, such as Alzheimer's dementia,
type II diabetes and dialysis related amyloidosis. It is now widely
believed that the misfolding and aggregation of amyloid-like proteins
underlies the pathologies of these different diseases. Senexis has
discovered potent and selective compounds that protect cells and
tissues from the toxic forms of amyloid. Senexis is funded by BTG
plc and the Wellcome Trust. Further information on Senexis can be
found at www.senexis.com.
|
